CD19/CD22/BCMA CAR-T therapy

CAR-T therapy targeting CD19, CD22, and BCMA · Shanghai Cell Therapy Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD19/CD22/BCMA CAR-T therapy, covering 2025-08-21 to 2025-08-21. Get the full timeline:

Most recent: Clinical Trial Update: A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) [EARLY_Phase 1]

See pricing